Genetically-modified dendritic cells serve as effective adjuvants in promoting antitumor immunity in vitro and in vivo

Keyphrases

• Genetic Modification 100%
• Tumor Immunity 100%
• Dendritic Cells 100%
• Interleukin-12 (IL-12) 100%
• Cell-based 50%
• T Cells 50%
• Tumor 50%
• Sarcoma 50%
• Immunogenicity 50%
• Tumor Antigen 50%
• Interferon-α (IFN-α) 50%
• Clinical Response 50%
• Interleukin-4 (IL-4) 50%
• Stable Disease 50%
• Peptide-MHC Complex 50%
• Murine Bone Marrow 50%
• Extended Period 50%
• Therapy Models 50%
• Bone Marrow-derived Dendritic Cells 50%
• Immunogenic Tumor 50%
• Peptide Drugs 50%
• Tumor Peptides 50%
• Stimulatory Capacity 50%
• Gene Gun 50%
• Mild Acid Elution 50%
• Tumor-associated 50%
• T-cell Epitope 50%
• Therapeutic Impact 50%
• Follicular Dendritic Cell Tumor 50%
• Poorly Immunogenic Tumors 50%

Immunology and Microbiology

• Dendritic Cell 100%
• Adjuvant 100%
• In Vitro 100%
• Cytokine 66%
• Peptides 66%
• Immunogenicity 33%
• Tumor Immunity 33%
• Epitope 33%
• Elution 33%
• Bone Marrow Derived Dendritic Cell 33%
• Dendritic Cell Vaccine 33%
• T Cell 33%
• Wild Type 33%
• Interleukin 4 33%
• Tumor Antigen 33%